# PUBLIC SUMMARY DOCUMENT

**Product:** Omnigon Welland Aurum Plus - Urostomy

**Applicant:** Omnigon

**Date of SPAP Meeting:** 20 October 2020

## Proposed Listing on the Stoma Appliance Scheme

The applicant, Omnigon sought listing of the Omnigon Welland Aurum Plus - Urostomy in subgroup 3(a) of the Stoma Appliance Scheme (SAS) Schedule. The proposed product, including 18 variants, was proposed for listing at a unit price of $4.674, with a maximum monthly quantity of 60 units.

## Comparator

The applicant nominated the Omnigon Welland Aurum (SAS code 80095M) as the comparator. The product is currently listed in subgroup 3(a) of the SAS Schedule at the unit price of $4.674, with a maximum monthly quantity of 60 units. The Stoma Product Assessment Panel (SPAP) accepted this product as an acceptable comparator

## Background

This was the SPAP’s first consideration of this product.

## Clinical Place for the Product

The proposed product is an alternative for users requiring a one-piece urostomy pouch.

## SPAP Comment

### Clinical Analysis

The Panel noted that the proposed product is a new version of the currently listed Aurum (flat) range on the SAS Schedule. The Panel also noted the applicant’s claim that the new design of the closure for the Aurum Plus (flat) drainable range makes the drainable outlet easier to open and close whilst maintaining security of the closure.

The proposed product is considered to be equivalent to products currently available at the benchmark price in subgroup 3(a)

### Economic Analysis

Not undertaken.

### Financial Analysis

Listing of this product is recommended on a cost-minimisation basis compared to products currently listed in subgroup 3(a) of the SAS Schedule. It is therefore, unlikely that there would be any budgetary impact for the SAS as a consequence of listing this product.

## SPAP Recommendation

The SPAP recommended that the Omnigon Welland Aurum Plus - Urostomy, including 18 variants be listed in subgroup 3(a) of the SAS Schedule at the unit price of $4.674, with a maximum monthly quantity of 60 units. In view of the sponsor’s claim that this product range has some benefit for patients, the SPAP sought advice whether this product range would replace the comparator on the SAS Schedule.

## Context for Decision

The SPAP helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context. A SPAP decision not to recommend listing or changes to a listing does not represent a final SPAP view about the merits of a particular stoma product. A company can resubmit to the SPAP following a decision not to recommend listing or changes to a listing. The SPAP is an advisory committee and as such its recommendations are non-binding on Government. All SPAP recommendations are subject to Cabinet/Ministerial approval.

## Applicant’s Comment

Omnigon agrees with the Panel’s recommendation.